Research programme: melanocortin receptor antagonists - Taisho

Drug Profile

Research programme: melanocortin receptor antagonists - Taisho

Alternative Names: Anti-anxiety therapy - Taisho; MCL 0129

Latest Information Update: 04 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical
  • Class Piperazines
  • Mechanism of Action Melanocortin type 4 receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 04 Oct 2013 Discontinued - Preclinical for Anxiety disorders in Japan (unspecified route)
  • 04 Oct 2013 Discontinued - Preclinical for Major depressive disorder in Japan (unspecified route)
  • 31 Dec 2009 No development reported - Preclinical for Anxiety disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top